Last updated: February 23, 2026
What is NDC 60758-0773?
NDC 60758-0773 refers to a specific drug product listed in the U.S. National Drug Code (NDC) database. Based on available data, this code corresponds to a branded or generic pharmaceutical, likely a biologic or small-molecule drug, used for specific indications. Exact information about the drug's name, manufacturer, and formulation is essential for analyzing its market and pricing.
Note: There is limited publicly available detailed data on this exact NDC. Due to this, the following analysis synthesizes typical market factors affecting similar drugs within its class.
How does the drug's indication influence its market?
The drug's primary therapeutic use determines its market size, competitive landscape, and pricing strategies.
| Therapeutic Area |
Estimated Market Size (Global) |
Market Dynamics |
| Oncology |
Approx. $150 billion |
High demand, significant competition, premium pricing |
| Autoimmune diseases |
Approx. $100 billion |
Expanding biologic approvals, high insurance coverage |
| Rare diseases |
$20-50 billion |
High prices due to limited competition |
Assessment: If NDC 60758-0773 is used for oncology or autoimmune conditions, it likely targets a large and competitive market with potential for premium pricing.
Market Players and Competition
The competitive landscape depends on the drug’s class and formulation.
Main competitors:
- Existing biologics or small molecules with similar mechanisms.
- Biosimilars if applicable.
- Established market leaders (e.g., Amgen, Genentech, Pfizer).
Market penetration factors:
- Patent status: If the drug's patent has expired or is nearing expiration, biosimilar entry can lead to price erosion.
- Regulatory approvals and exclusivity: Data exclusivity and orphan drug designation influence market duration and prices.
- Clinical advantages: Proven superior efficacy or safety can command higher prices.
Regulatory and Pricing Policies Impact
Pricing enforcement:
- Medicare and Medicaid Price Negotiations: Recent policies aim to lower drug prices for government programs.
- Inflation-based price caps: Legislation links prices to inflation for certain biologics.
Reimbursement landscape:
- Coverage depends on formulary placement, clinical evidence, and negotiations with payers.
- High-cost therapies often face denials or step therapy requirements.
Current Price Landscape
Assuming NDC 60758-0773 is a biologic or specialty drug, typical wholesale acquisition costs (WAC) and list prices can inform projections.
| Price Range |
Drug Type |
Notes |
| $10,000-$20,000/month |
Biologics for autoimmune conditions |
Premium pricing, patient assistance programs common |
| $5,000-$12,000/month |
Oncology biologics |
Dependent on indication, therapy line |
| $2,000-$8,000/month |
Biosimilars |
Generally 20-50% lower than originator |
Example: If NDC 60758-0773 is a biologic for rheumatoid arthritis, its list price could be approximately $15,000/month, with negotiated discounts reducing actual payer costs.
Price Projection Trends
Over the next five years, key factors influencing price trajectory include:
- Patent expirations: Loss of patent protections typically result in a 20-50% price decline as biosimilars or generics enter the market.
- Regulatory changes: Enhanced price controls or reforms may limit annual price increases.
- Market penetration: Increased adoption can stabilize or slightly reduce per-unit costs due to economies of scale.
- Competitive biosimilars: Entry reduces price but may increase access and volume.
Projected Price Adjustment (2023-2028):
| Year |
Estimated Price Range |
Trend |
| 2023 |
$15,000/month |
Stable, high demand |
| 2024 |
$13,500-$14,500/month |
Slight decline due to biosimilar entry |
| 2025 |
$11,000-$13,000/month |
Increased biosimilar competition |
| 2026 |
$9,000-$11,000/month |
Continued biosimilar proliferation |
| 2027 |
$8,000-$10,000/month |
Market stabilization with multiple options |
Summary of Market Opportunities
- Consider the degree of patent protection and patent cliffs.
- Examine the competitive landscape and biosimilar approval status.
- Assess payer strategies and formulary placements.
- Track legislative efforts around drug pricing and reimbursement policies.
Key Takeaways
- The drug’s market size largely depends on its indication and target patient population.
- Competitive pressure from biosimilars and generic equivalents influences pricing trends.
- Policy shifts may impose price caps or negotiate discounts, impacting revenue potential.
- Price projections indicate moderate declines as biosimilars gain market share.
- Revenue opportunity hinges on exclusivity, clinical differentiation, and market access strategies.
FAQs
1. What factors affect the pricing of this drug?
Patent status, competition, regulatory policies, reimbursement landscape, and clinical benefits.
2. How do biosimilars impact the market price?
They typically decrease the originator’s price by 20-50%, increasing access but reducing margins for innovators.
3. When is significant price erosion expected?
Following patent expiration, usually 8-12 years post-launch, depending on patent extensions and litigation.
4. Are government policies likely to influence future prices?
Yes. Legislation aiming to control healthcare costs can limit annual price increases or enforce price negotiations.
5. What is the potential market size for this drug?
Depending on the therapeutic area, from hundreds of millions to billions of dollars globally.
References
[1] IQVIA. (2022). Global Market Report.
[2] FDA. (2023). Biologics and Biosimilars.
[3] CMS. (2022). Drug Pricing and Reimbursement Policies.
[4] EvaluatePharma. (2022). Forecasts for Specialty Drugs.
[5] Centers for Medicare & Medicaid Services. (2022). Medicare Price Negotiation Policies.
